European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS)
Restricted accessResearch articleFirst published online January, 2017
European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS)
WolfPADawberTRThomasHEJrKannelWB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology1978; 28: 973–7.
2.
KrahnADManfredaJTateRBMathewsonFACuddyTE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-up Study. Am J Med1995; 98: 476–84.
3.
OttABretelerMMde BruyneMCvan HarskampFGrobbeeDEHofmanA. Atrial fibrillation and dementia in a population-based study: the Rotterdam Study. Stroke1997; 28: 316–21.
4.
MiyasakaYBarnesMEPetersenRCChaSSBaileyKRGershBJ, et al.. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J2007; 28: 1962–7.
5.
SolimanEZLopezFO’NealWTChenLYBengtsonLZhangZM, et al.. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: The Atherosclerosis Risk in Communities (ARIC) study. Circulation2015; 131: 1843–50.
6.
SolimanEZSaffordMMMuntnerPKhodnevaYDawoodFZZakaiNA, et al.. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med2014; 174: 107–14.
7.
BenjaminEJWolfPAD’AgostinoRBSilbershatzHKannelWBLevyD. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation1998; 98: 946–52.
8.
BenjaminEJChenPSBildDEMascetteAMAlbertCMAlonsoA, et al.. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation2009; 119: 606–18.
9.
WolowaczSESamuelMBrennanVKJasso-MosquedaJGVan GelderIC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace2011; 13: 1375–85.
10.
BorianiGManiadakisNAuricchioAMüller-RiemenschneiderFFattoreGLeyvaF, et al.. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. Eur Heart J2013; 34: 1869–74.
11.
ManiadakisNVardasPMantovaniLGFattoreGBorianiG. Economic evaluation in cardiology. Europace2011; 13(Suppl 2): ii3–8.
12.
FattoreGManiadakisNMantovaniLGBorianiG. Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. Europace2011; 13(Suppl 2): ii49–53.
13.
BorianiGDiembergerIMartignaniCBiffiMBranziA. The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems. EurHeart J2006; 27: 893–4.
14.
SchnabelRBYinXGonaPLarsonMGBeiserASMcManusDD, et al.. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet2015; 386: 154–62.
15.
ChughSSHavmoellerRNarayananKSinghDRienstraMBenjaminEJ, et al.. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation2014; 129: 837–47.
16.
BorianiGDiembergerI. Globalization of the epidemiologic, clinical, and financial burden of atrial fibrillation. Chest2012; 142: 1368–70.
17.
WeintraubWSDanielsSRBurkeLEFranklinBAGoffDCJrHaymanLL, et al.. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation2011; 124: 967–90.
18.
HuxleyRRLopezFLFolsomARAgarwalSKLoehrLRSolimanEZ, et al.. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation2011; 123: 1501–8.
19.
DaveDKaestnerR. Health insurance and ex ante moral hazard: evidence from Medicare. Int J Health Care Finance Econ2009; 9: 367–90.
20.
DublinSFrenchBGlazerNLWigginsKLLumleyTPsatyBM, et al.. Risk of new onset atrial fibrillation in relation to body mass index. Arch Intern Med2006; 166: 2322–8.
21.
LongMJJiangCQLamTHXuLZhangWSLinJMai. Atrial fibrillation and obesity among older Chinese: the Guangzhou Biobank Cohort Study. Int J Cardiol2011; 148: 48–52.
22.
TedrowUBConenDRidkerPMCookNRKoplanBAMansonJEai. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (Women’s Health Study). JAmCollCardiol2010; 55: 2319–27.
23.
WangTJPariseHLevyDD’AgostinoRBSrWolfPAVasanRS, et al.. Obesity and the risk of new-onset atrial fibrillation. JAMA2004; 292: 2471–7.
24.
FrostLBenjaminEJFenger-GrønMPedersenATjønnelandAOvervadK. Body fat, body fat distribution, lean body mass and atrial fibrillation and flutter. A Danish cohort study. Obesity (Silver Spring)2014; 22: 1546–52.
25.
VermondRAGeelhoedBVerweijNTielemanRGVan der HarstPHillegeHL, et al.. Incidence of atrial fibrillation and relation with cardiovascular events, heart failure and mortality – a community-based studyfrom the Netherlands. J Am Coll Cardiol2015; 66: 1000–7.
26.
AbedHSWittertGALeongDPShiraziMGBahramiBMiddeldorpME, et al.. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA2013; 310: 2050–60.
27.
PathakRKElliotAMiddeldorpMEMeredithMMehtaABMahajanR, et al.. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol2015; 66: 985–96.
28.
PathakRKMiddeldorpMEMeredithMMehtaABMahajanRWongCX, et al.. Long-term Effect of Goal-Directed Weight Management in an Atrial Fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol2015; 65: 2159–69.
29.
RienstraMSunJXLubitzSAFrankelDSVasanRSLevyD, et al.. Plasma resistin, adiponectin, and risk of incident atrial fibrillation : the Framingham Offspring Study. Am Heart J2012; 163: 119–24.
30.
NyrnesAMathiesenEBNjolstadIWilsgaardTLochenML. Palpitations are predictive of future atrial fibrillation. An 11-year follow-up of 22,815 men and women: the Tromso study. Eur J Prev Cardiol2013; 20: 729–36.
31.
HuxleyRRFilionKBKonetySAlonsoA. Meta-analysis of cohort and case control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol2011; 108: 56–62.
32.
CoromilasJ. Obesity and atrial fibrillation: is one epidemic feeding the other?JAMA2004; 292: 2519–20.
33.
OvervadTFRasmussenLHSkjøthFOvervadKLipGYLarsenTB. Body mass index and adverse events in patients with incident atrial fibrillation. Am JMed2013; 126. 640.e9-17.
34.
BadhekaAORathodAKizilbashMAGargNMohamadTAfonsoL, et al.. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am JMed2010; 123: 646–51.
35.
ShenJJohnsonVMSullivanLMJacquesPFMagnaniJWLubitzSA, et al.. Dietary factors and incident atrial fibrillation: the Framingham Heart Study. Am J Clin Nutr2011; 93: 261–6.
36.
KhawajaOGazianoJMDjousseL. Nut consumption and risk of atrial fibrillation in the Physicians’ Health Study. NutrJ2012; 11: 17–17.
37.
FrettsAMMozaffarianDSiscovickDSHeckbertSRMcKnightBKingIB, et al.. Associations of plasma phospholipid and dietary alpha linoleic acid with incident atrial fibrillation in older adults: The Cardiovascular Health Study. J Am Heart Assoc2013; 2: e003814–e003814.
38.
CostanzoSDe CurtisAdi NiroVOlivieriMMorenaMDe FilippoCM, et al.. on behalf of the Polyphemus Observational Study Investigators. Postoperative atrial fibrillation and total dietary antioxidant capacity in patients undergoing cardiac surgery: the Polyphemus Observational Study. J Thorac Cardiovasc Surg2015; 149: 1175–82.
39.
MattioliAVMiloroCPennellaSPedrazziPFarinettiA. Adherence to Mediterranean diet and intake of antioxidants influence spontaneous conversion of atrial fibrillation. NutrMetab Cardiovasc Dis2013; 23: 115–21.
40.
PastoriDCarnevaleRBarimocciaSNocellaCTanzilliGCangemiR, et al.. Does Mediterranean diet reduce cardiovascular events and oxidative stress in atrial fibrillation?Antioxid Redox Signal2015; 23: 682–7.
41.
Martínez-GonzálezMAToledoEArósFFiolMCorellaDSalas-SalvadóJ, et al.. Extra-virgin olive oil consumption reduces risk of atrial fibrillation. The PREDIMED (Prevencion con Dieta Mediterranea) Trial. Circulation2014; 130: 18–26.
42.
Al SuwaidiJZubaidMAl-MahmeedWAAl-RashdanIAminHBenerA, et al.. Impact of fasting in Ramadan in patients with cardiac disease. Saudi Med J2005; 26: 1579–83.
43.
Van WagonerDRPicciniJPAlbertCMAndersonMEBenjaminEJBrundelB, et al.. Progress toward the prevention and treatment of atrial fibrillation: a summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9–10, 2013. Heart Rhythm2015; 12: e5–29.
44.
LopezFLAgarwalSKMaclehoseRFSolimanEZSharrettARHuxleyRR, et al.. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol2012; 5: 155–62.
45.
AlonsoAYinXRoetkerNSMagnaniJWKronmalRAEllinorPT, et al.. Blood lipids and the incidence of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study. J Am Heart Assoc2014; 3: e001211–e001211.
46.
GronroosNNChamberlainAMFolsomARSolimanEZAgarwalSKNettletonJA, et al.. Fish, fish-derived n-3 fatty acids, and risk of incident atrial fibrillation in the Atherosclerosis Risk in Communities (ARIC) study. PLoS One2012; 7: e36686–e36686.
47.
RixTAJoensenAMRiahiSLundbye-ChristensenSTjønnelandASchmidtEB, et al.. A U-shaped association between consumption of marine n-3 fatty acids and development of atrial fibrillation/atrial flutter-a Danish cohort study. Europace2014; 16: 1554–61.
48.
RixTAJoensenAMRiahiSLundbye-ChristensenSOvervadKSchmidtEB. Marine n-3 fatty acids in adipose tissue and development of atrial fibrillation: a Danish cohort study. Heart2013; 99: 1519–24.
49.
VirtanenJKMursuJVoutilainenSTuomainenTP. Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation2009; 120: 2315–21.
50.
Young-XuYJabbourSGoldbergRBlattCMGraboysTBilchikB, et al.. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol2003; 92: 1379–83.
51.
Shiroshita-TakeshitaASchramGLavoieJNattelS. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation2004; 110: 2313–9.
52.
KumagaiKNakashimaHSakuK. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res2004; 62: 105–11.
53.
ElgendyIYMahmoudAHuoTBeaverTMBavryAA. Meta-analysis of 12 trials evaluating the effects of statins on decreasing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol2015; 115: 1523–8.
54.
JacobKANathoeHMDielemanJMvan OschDKluinJvan DijkD. Inflammation in new-onset atrial fibrillation after cardiac surgery: a systematic review. Eur J Clin Invest2014; 44: 402–28.
55.
RahimiKEmbersonJMcGalePMajoniWMerhiAAsselbergsFW, et al.. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ2011; 342: d1250–d1250.
56.
FauchierLClementyNBabutyD. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol2013; 28: 7–18.
57.
StoneNJRobinsonJGLichtensteinAHBairey MerzCNBlumCBEckelRH, et al.. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014; 129: S1–45.
58.
MozaffarianDPsatyBMRimmEBLemaitreRNBurkeGLLylesMF, et al.. Fish intake and risk of incident atrial fibrillation. Circulation2004; 110: 368–73.
59.
SakabeMShiroshita-TakeshitaAMaguyADumesnilCNigamALeungTK, et al.. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation2007; 116: 2101–9.
60.
MayyasFSakuraiSRamRRennisonJHHwangESCastelL, et al.. Dietary omega3 fatty acids modulate the substrate for post-operative atrial fibrillation in a canine cardiac surgery model. Cardiovasc Res2011; 89: 852–61.
61.
MozaffarianDWuJHde Oliveira OttoMCSandesaraCMMetcalfRGLatiniR, et al.. Fish oil and post-operative atrial fibrillation: a meta-analysis of randomized controlled trials. J Am Coll Cardiol2013; 61: 2194–6.
62.
DarghosianLFreeMLiJGebretsadikTBianAShintaniA, et al.. Effect of omega-three polyunsaturated fatty acids on inflammation, oxidative stress, and recurrence of atrial fibrillation. Am J Cardiol2015; 115: 196–201.
63.
NigamATalajicMRoyDNattelSLambertJNozzaA, et al.. Fish oil for the reduction of atrial fibrillation recurrence, inflammation and oxidative stress. J Am Coll Cardiol2014; 64: 1441–8.
64.
VisioliFRisePBarassiMCMarangoniFGalliC. Dietary intake offish vs. formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids2003; 38: 415–8.
65.
CammAJKirchhofPLipGYSchottenUSavelievaIErnstS, et al.. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Europace2010; 12: 1360–420.
66.
EckelRHJakicicJMArdJDde JesusJMHouston MillerNHubbardVS, et al.. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol2014; 63: 2960–84.
67.
PeppardPEYoungTBarnetJHPaltaMHagenEWHlaKM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol2013; 177: 1006–14.
68.
SomersVKWhiteDPAminRAbrahamWTCostaFCulebrasA, et al.. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation2008; 118: 1080–111.
69.
GamiASHodgeDOHergesRMOlsonEJNykodymJKaraT, et al.. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol2007; 49: 565–71.
70.
CadbyGMcArdleNBriffaTHillmanDRSimpsonLKnuimanM, et al.. Severity of OSA is an independent predictor ofincident atrial fibrillation hospitalization in a large sleep-clinic cohort. Chest2015; 148: 945–52.
GhiasMScherlagBJLuZNiuGMoersAJackmanWM, et al.. The role of ganglionated plexi in apnea-related atrial fibrillation. J Am Coll Cardiol2009; 54: 2075–83.
73.
RocheFXuongANCourt-FortuneICostesFPichotVDuverneyD, et al.. Relationship among the severity of sleep apnea syndrome, cardiac arrhythmias, and autonomic imbalance. Pacing Clin Electrophysiol2003; 26: 669–77.
74.
FeinASShvilkinAShahDHaffajeeCIDasSKumarK, et al.. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol2013; 62: 300–5.
75.
NeilanTGFarhadHDodsonJAShahRVAbbasiSABakkerJP, et al.. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc2013; 2: e000421–e000421.
76.
GrimmWHoffmannJMenzVKöihlerUHeitmannJPeterJH, et al.. Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. Am J Cardiol1996; 77: 1310–4.
77.
SimantirakisENSchizaSIMarketouMEChrysostomakisSIChlouverakisGIKlapsinosNC, et al.. Severe bradyarrhythmias in patients with sleep apnoea: the effect of continuous positive airway pressure treatment: a long-term evaluation using an insertable loop recorder. Eur Heart J2004; 25: 1070–6.
78.
NaruseYTadaHSatohMYanagiharaMTsuneokaHHirataY, et al.. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm2013; 10: 331–7.
79.
LiLWangZWLiJGeXGuoLZWangY, et al.. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace2014; 16: 1309–14.
80.
KhanALatifFHawkinsBTawkMSivaramCAKinasewitzG. Effects of obstructive sleep apnea treatment on left atrial volume and left atrial volume index. Sleep Breath2008; 12: 141–7.
81.
MaenoKKasagiSUedaAKawanaFIshiwataSOhnoM, et al.. Effects ofobstructive sleep apnea and its treatment on signal-averaged P-wave duration in men. Circ Arrhythm Electrophysiol2013; 6: 287–93.
82.
AriasMAGarcía-RíoFAlonso-FernándezAMedianoOMartínezIVillamorJ. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation2005; 112: 375–83.
83.
ShuklaAAizerAHolmesDFowlerSParkDSBernsteinS, et al.. Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis. JACC-CEP2015; 1: 41–51.
84.
CowieMRWoehrleHWegscheiderKAngermannCd’OrthoMPErdmannE, et al.. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med2015; 373: 1095–105.
85.
BenjaminEJLevyDVaziriSMD’AgostinoRBBelangerAJWolfPA, et al.. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA1994; 271: 840–4.
86.
ThomasMDDublinSKaplanRCGlazerNLLumleyTLongstrethWTJr, et al.. Blood pressure control and risk ofincident atrial fibrillation. Am J Hypertens2008; 21: 1111–6.
87.
WachtellKLehtoMGerdtsEOlsenMHHornestamBDahlöfB, et al.. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol2005; 45: 712–9.
88.
MarottSCWNielsenSFBennMNordestgaardBG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J2014; 35: 1205–14.
89.
OkinPMHilleDALarstorpACKWachtellKKjeldsenSEDahlofB, et al.. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension2015; 66: 368–73.
90.
The GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med2009; 360: 1606–17.
91.
GoetteASchonNKirchhofPBreithardtGFetschTHauslerKG, et al.. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol2012; 5: 43–51.
92.
LipGYFrisonLGrindM. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation. J Intern Med2007; 261: 577–86.
93.
EmdinCACallenderTCaoJRahimiK. Effect ofantihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials. Europace2015; 17: 701–10.
94.
GillisAM. Angiotensin-receptor blockers for prevention of atrial fibrillation – a matter of timing or target?N Engl J Med2009; 360: 1669–71.
95.
MayyasFAlzoubiKHVan WagonerDR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol2013; 168: 5135–42.
96.
KhatibRJosephPBrielMYusufSHealeyJ. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol2013; 165: 17–24.
97.
MenezesARLavieCJDiNicolantonioJJO’KeefeJMorinDPKhatibS, et al.. Atrial fibrillation inthe21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc2013; 88: 394–409.
98.
AlonsoAKrijtheBPAspelundTStepasKAPencinaMJMoserCB, et al.. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc2013; 2: e000102–e000102.
99.
HuxleyRRAlonsoALopezFLFilionKBAgarwalSKLoehrLR, et al.. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart2012; 98: 133–8.
100.
OstgrenCJMerloJRastamLLindbladU. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab2004; 6: 367–74.
101.
PfisterRMichelsGCairnsRSchneiderCAErdmannE. Incidence of new onset bundle branch block and atrial fibrillation in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study. Int J Cardiol2011; 153: 233–4.
102.
SchoenTPradhanADAlbertCMConenD. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol2012; 60: 1421–8.
103.
DublinSGlazerNLSmithNLPsatyBMLumleyTWigginsKL, et al.. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med2010; 25: 853–8.
104.
AksnesTASchmiederREKjeldsenSEGhaniSHuaTAJuliusS. Impact of new onset diabetes mellitus on development of atrial fibrillation and heart failure in high risk hypertension (from the VALUE Trial). Am J Cardiol2008; 101: 634–8.
105.
ChangSHWuLSChiouMJLiuJRYuKHKuoCF, et al.. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol2014; 13: 123–123.
106.
OvervadTFSkjøthFLipGYHLaneDAAlbertsenIERasmussenLH, et al.. Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study. Stroke2015; 46: 2168–74.
107.
AnselminoMMattaMD’ascenzoFPapponeCSantinelliVBunchTJ, et al.. Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis. Europace2015; 17: 1518–25.
108.
ChamberlainAMAgarwalSKFolsomARDuvalSSolimanEZAmbroseM, et al.. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm2011; 8: 1160–6.
109.
PfisterRBragelmannJMichelsGWarehamNJLubenRKhawKT. Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort. Eur J Prev Cardiol2015; 22: 932–9.
110.
FribergJBuchPScharlingHGadsbphiollNJensenGB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology2003; 14: 666–72.
RodriguezCJSolimanEZAlonsoASwettKOkinPMGoffDCJr, et al.. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: The Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol2015; 25: 71–6.
113.
SuzukiSOtsukaTSagaraKKanoHMatsunoSTakaiH, et al.. Association between smoking habits and the first-time appearance of atrial fibrillation in Japanese patients: evidence from the Shinken database. J Cardiol2015; 66: 73–9.
114.
HeeringaJKorsJAHofmanAvan RooijFJWittemanJC. Cigarette smoking and risk of atrial fibrillation: the Rotterdam study. Am Heart J2008; 156: 1163–9.
115.
SchnabelRBSullivanLMLevyDPencinaMJMassaroJMD’AgostinoRB, et al.. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet2009; 373: 739–45.
116.
PsatyBMManolioTAKullerLHKronmalRACushmanMFriedLP, et al.. Incidence of and risk factors for atrial fibrillation in older adults. Circulation1997; 96: 2455–61.
117.
FrostLHuneLJVestergaardP. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health study. Am J Med2005; 118: 489–95.
118.
WilhelmsenLRosengrenALappasG. Hospitalizations for atrial fibrillation in the general male population: Morbidity and risk factors. J Intern Med2001; 250: 382–9.
119.
StewartSHartCLHoleDJMcMurrayJJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart2001; 86: 516–21.
120.
HergensMPGalantiRHanssonJFredlundPAhlbomAAlfredssonL, et al.. Use of Scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation. Epidemiology2014; 25: 872–6.
121.
DixitSPletcherMJVittinghoffEImburgiaKMaguireCWhitmanIR, et al.. Second hand smoke and atrial fibrillation: data from the health Eheart study. Heart Rhythm2016; 13: 3–9.
122.
OkumuraY. Smoking and the risk of the perpetuation of atrial fibrillation: under debate in large cohort studies. Heart Rhythm2011; 8: 1167–8.
123.
MonroyAEHommelESmithSTRajiM. Paroxysmal atrial fibrillation following electronic cigarette use in an elderly woman. Clin Geriatr2012; 20: 28–32.
124.
O’NealWTQureshiWTJuddSEMcClureLACushmanMHowardVJ, et al.. Environmental tobacco smoke and atrial fibrillation: The REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. J Occup Environ Med2015; 57: 1154–8.
125.
RigottiNAEagleKA. Atrial fibrillation while chewing nicotine gum. JAMA1986; 255: 1018–1018.
LevitzkyYSGuoCYRongJLarsonMGWalterREKeaneyJFJr, et al.. Relation of smoking status to a panel of inflammatory markers: the Framingham offspring. Atherosclerosis2008; 201: 217–24.
129.
TuanTCChangSLTaiCTLinYJHuYFLoLW, et al.. Impairment of the atrial substrates by chronic cigarette smoking in patients with atrial fibrillation. J Cardiovasc Electrophysiol2008; 19: 259–65.
130.
HayashiHOmichiCMiyauchiYMandelWJLinSFChenPS, et al.. Age-related sensitivity to nicotine for inducible atrial tachycardia and atrial fibrillation. Am J Physiol Heart Circ Physiol2003; 285: H2091–8.
131.
GoetteA. Nicotine, atrial fibrosis, and atrial fibrillation: do microRNAs help to clear the smoke?Cardiovasc Res2009; 83: 421–2.
132.
GoetteALendeckelUKuchenbeckerABukowskaAPetersBKleinHU, et al.. Cigarette smoking induces atrial fibrosis in humans via nicotine. Heart2007; 93: 1056–63.
133.
ShanHZhangYLuYZhangYPanZCaiB, et al.. Downregulation of mir-133 and mir-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res2009; 83: 465–72.
134.
BuchPFribergJScharlingHLangePPrescottE. Reduced lung function and risk of atrial fibrillation in the Copenhagen city heart study. Eur Respir J2003; 21: 1012–6.
135.
LiJAgarwalSKAlonsoABleckerSChamberlainAMLondonSJ, et al.. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation2014; 129: 971–80.
136.
BosdrieszJRWillemsenMCStronksKKunstAE. Socioeconomic inequalities in smoking cessation in 11 European countries from 1987 to 2012. J Epidemiol Community Health2015; 69: 886–92.
137.
HitchmanSCFongGTZannaMPThrasherJFChung-HallJSiahpushM. Socioeconomic status and smokers’ number of smoking friends: Findings from the international tobacco control (itc) four- country survey. Drug Alcohol Depend2014; 143: 158–66.
138.
ZollerBLiXSundquistJSundquistK. Neighbourhood deprivation and hospitalization for atrial fibrillation in Sweden. Europace2013; 15: 1119–27.
139.
MisialekJRRoseKMEverson-RoseSASolimanEZClarkCJLopezFL, et al.. Socioeconomic status and the incidence of atrial fibrillation in whites and blacks: the Atherosclerosis Risk in Communities (ARIC) study. J Am Heart Assoc2014; 3: e001159–e001159.
140.
PicciniJPHammillBGSinnerMFHernandezAFWalkeyAJBenjaminEJ, et al.. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. Eur Heart J2014; 35: 250–6.
141.
SchnabelRBRienstraMSullivanLMSunJXMoserCBLevyD, et al.. Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail2013; 15: 843–9.
142.
PotparaTSPolovinaMMLicinaMMMarinkovicJMLipGY. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade atrial fibrillation study. EurJ Heart Fail2013; 15: 415–24.
143.
LipGYFrisonLHalperinJLLaneDA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke2010; 41: 2731–8.
144.
NakagawaKHiraiTOharaKFukudaNNumaSTaguchiY, et al.. Impact of persistent smoking on long-term outcomes in patients with nonvalvular atrial fibrillation. J Cardiol2015; 65: 429–33.
145.
WangTJMassaroJMLevyDVasanRSWolfPAD’AgostinoRB, et al.. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA2003; 290: 1049–56.
146.
AngoulvantDVillejoubertOBejan-AngoulvantTIvanesFSaint EtienneCLipGY, et al.. Effect of active smoking on comparative efficacy of antithrombotic therapy in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest2015; 148: 491–8.
147.
HuangYBrittonJHubbardRLewisS. Who receives prescriptions for smoking cessation medications? An association rule mining analysis using a large primary care database. Tob Control2013; 22: 274–9.
148.
PathakRKMiddeldorpMELauDHMehtaABMahajanRTwomeyD, et al.. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol2014; 64: 2222–31.
149.
NewbyDEMannucciPMTellGSBaccarelliAABrookRDDonaldsonK, et al.. ESC Working Group on Thrombosis, European Association for Cardiovascular Prevention and Rehabilitation; ESC Heart Failure Association. Expert position paper on air pollution and cardiovascular disease. Eur Heart J2015; 36: 83–93b.
150.
RajagopalanSBrookRD. Air pollution and type 2 diabetes: mechanistic insights. Diabetes2012; 61: 3037–45.
151.
BrookRDRajagopalanSPopeCABhatnagarAIIIDiez-RouxAVHolguinF, et al.. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation2010; 121: 2331–78.
152.
BrookRDRajagopalanS. Particulate matter, air pollution, and blood pressure. J Am Soc Hypertens2009; 3: 332–50.
153.
PopeCAIIITurnerMCBurnettRTJerrettMGapsturSMDiverWR, et al.. Relationships between fine particulate air pollution, cardiometabolic disorders, and cardiovascular mortality. Circ Res2015; 116: 108–15.
154.
PetersAFrohlichMDoringAImmervollTWichmannHEHutchinsonWL, et al.. Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J2001; 22: 1198–204.
155.
WelleniusGABurgerMRCoullBASchwartzJSuhHHKoutrakisP, et al.. Ambient air pollution and the risk of acute ischemic stroke. Arch Intern Med2012; 172: 229–34.
156.
O’DonnellMJFangJMittlemanMAKapralMKWelleniusGA. Fine particulate air pollution (PM2.5) and the risk of acute ischemic stroke. Epidemiology2011; 22: 422–31.
157.
WelleniusGASchwartzJMittlemanMA. Air pollution and hospital admissions for ischemic and hemorrhagic stroke among medicare beneficiaries. Stroke2005; 36: 2549–53.
158.
MilojevicAWilkinsonPArmstrongBBhaskaranKSmeethLHajatS. Shortterm effects of air pollution on a range of cardiovascular events in England and Wales: case-crossover analysis of the MINAP database, hospital admissions and mortality. Heart2014; 100: 1093–8.
159.
BunchTJHorneBDAsirvathamSJDayJDCrandallBGWeissJP, et al.. Atrial fibrillation hospitalization is not increased with short-term elevations in exposure to fine particulate air pollution. Pacing Clin Electrophysiol2011; 34: 1475–9.
160.
LinkMSLuttmann-GibsonHSchwartzJMittlemanMAWesslerBGoldDR, et al.. Acute exposure to air pollution triggers atrial fibrillation. J Am Coll Cardiol2013; 62: 816–25.
161.
RichDQMittlemanMALinkMSSchwartzJLuttmann-GibsonHCatalanoPJ, et al.. Increased risk of paroxysmal atrial fibrillation episodes associated with acute increases in ambient air pollution. Environ Health Perspect2006; 114: 120–3.
162.
RashidAHinesMScherlagBJYamanashiWSLovalloW. The effects of caffeine on the inducibility of atrial fibrillation. J Electrocardiol2006; 39: 421–5.
163.
NewcombePFRentonKWRautaharjuPMSpencerCAMontagueTJ. High dose caffeine and cardiac rate and rhythm in normal subjects. Chest1988; 94: 90–4.
164.
StrubeltODiederichKW. Experimental treatment of the acute cardiovascular toxicity of caffeine. J Toxicol Clin Toxicol1999; 37: 29–33.
165.
DonnersteinRLZhuDSamsonRBenderAMGoldbergSJ. Acute effects of caffeine ingestion on signal-averaged electrocardiograms. Am Heart J1998; 136(4 Pt 1): 643–6.
166.
ConenDChiuveSEEverettBMZhangSMBuringJEAlbertCM. Caffeine consumption and incident atrial fibrillation in women. Am J Clin Nutr2010; 92: 509–14.
167.
FrostLVestergaardP. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr2005; 81: 578–82.
168.
CaldeiraDMartinsCAlvesLBPereiraHFerreiraJJCostaJ. Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis of observational studies. Heart2013; 99: 1383–9.
169.
DiRJrDuringAMorelliPJHeydenMBiancanielloTA. Atrial fibrillation in healthy adolescents after highly caffeinated beverage consumption: two case reports. J Med Case Rep2011; 5: 18–18.
170.
EttingerPOWuCFDe La CruzCJrWeisseABAhmedSSReganTJ. Arrhythmias and the ‘Holiday Heart’: alcohol-associated cardiac rhythm disorders. Am Heart J1978; 95: 555–62.
171.
LiangYMenteAYusufSGaoPSleightPZhuJ, et al.. Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease. CMAJ2012; 184: E857–66.
172.
MandyamMCVedanthamVScheinmanMMTsengZHBadhwarNLeeBK, et al.. Alcohol and vagal tone as triggers for paroxysmal atrial fibrillation. Am J Cardiol2012; 110: 364–8.
173.
LaszloREickCSchwiebertMSchreinerBWeigHJWeretkaS, et al.. Alcohol-induced electrical remodeling: effects ofsustained short-term ethanol infusion on ion currents in rabbit atrium. Alcohol Clin Exp Res2009; 33: 1697–703.
174.
MakiTToivonenLKoskinenPNaveriHHarkonenMLeinonenH. Effect of ethanol drinking, hangover, and exercise on adrenergic activity and heart rate variability in patients with a history of alcohol-induced atrial fibrillation. Am J Cardiol1998; 82: 317–22.
175.
MukamalKJTolstrupJSFribergJJensenGGronbaekM. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation2005; 112: 1736–42.
176.
ConenDTedrowUBCookNRMoorthyMVBuringJEAlbertCM. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA2008; 300: 2489–96.
177.
DjousseLLevyDBenjaminEJBleaseSJRussALarsonMG, et al.. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol2004; 93: 710–3.
178.
LarssonSCDrcaNWolkA. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J Am Coll Cardiol2014; 64: 281–9.
179.
KodamaSSaitoKTanakaSHorikawaCSaitoAHeianzaY, et al.. Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol2011; 57: 427–36.
180.
ConenDAlbertCM. Alcohol consumption and risk of atrial fibrillation: how much is too much?J Am Coll Cardiol2014; 64: 290–2.
181.
DevlinRHenryJA. Clinical review: major consequences of illicit drug consumption. Crit Care2008; 12: 202–202.
182.
KorantzopoulosPLiuTPapaioannidesDLiGGoudevenosJA. Atrial fibrillation and marijuana smoking. Int J Clin Pract2008; 62: 308–13.
183.
KrishnamoorthySLipGYLaneDA. Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: a case series and literature review. Am J Med2009; 122: 851–6.e3.
184.
MadhokABoxerRChowdhuryD. Atrial fibrillation in an adolescent the agony of ecstasy. Pediatr Emerg Care2003; 19: 348–9.
185.
FurlanelloFSerdozLVCappatoRAmbroggiLD. Illicit drugs and cardiac arrhythmias in athletes. Eur J Cardiovasc Prev Rehab2007; 14: 487–94.
186.
LauDHStilesMKShashidharBJGlennDYoungGDSandersP. Atrial fibrillation and anabolic steroid abuse. Int J Cardiol2007; 117: e86–7.
GuglinMAljayehMSaiyadSAliRCurtisAB. Introducing a new entity: chemotherapy-induced arrhythmia. Europace2009; 11: 1579–86.
189.
Schjerning OlsenAMFosbølELPallisgaardJLindhardsenJLock HansenMKøberL, et al.. NSAIDs are associated with increased risk of atrial fibrillation in patients with prior myocardial infarction: a nationwide study. Eur Heart J Cardiovasc Pharmacother2015; 1: 107–14.
190.
SharmaAEinsteinAJVallakatiAArbab-ZadehAWalkerMDMukherjeeD, et al.. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Am J Cardiol2014; 113: 1815–21.
191.
KimDHRogersJRFulchinoLAKimCASolomonDHKimSC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One2015; 10: e0122646–e0122646.
192.
YalaciSTamerAKocayigitIGunduzH. Atrial fibrillation due to olanzapine overdose. Clin Toxicol2011; 49: 440–440.
193.
MartinRIPogoryelovaOKorefMSBourkeJPTeareMDKeavneyBD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart2014; 100: 1506–10.
194.
FarmakisDParissisJFilippatosG. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol2014; 63: 945–53.
195.
McCabePJ. Psychological distress in patients diagnosed with atrial fibrillation: the state of the science. J Cardiovasc Nurs2010; 25: 40–51.
196.
ThrallGLipGYCarrollDLaneD. Depression, anxiety, and quality of life in patients with atrial fibrillation. Chest2007; 132: 1259–64.
197.
HabibovicMVersteegHPelleAJTheunsDAJordaensLPedersenSS. Poor health status and distress in cardiac patients: the role of device therapy vs. underlying heart disease. Europace2013; 15: 355–61.
198.
von Eisenhart RotheAHuttFBaumertJBreithardtGGoetteAKirchhofP, et al.. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis–data from the German Competence Network on Atrial Fibrillation. Europace2015; 17: 1354–62.
199.
von Eisenhart RotheAFGoetteAKirchhofPBreithardtGLimbourgTCalvertM, et al.. Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enrolled in two large clinical trials. Europace2014; 16: 812–9.
200.
GehiAKSearsSGoliNWalkerTJChungESchwartzJ, et al.. Psychopathology and symptoms of atrial fibrillation: implications for therapy. J Cardiovasc Electrophysiol2012; 23: 473–8.
201.
PatelDMc ConkeyNDSohaneyRMcNeilAJedrzejczykAArmaganijanL. A systematic review of depression and anxiety in patients with atrial fibrillation: the mind-heart link. Cardiovasc Psychiatry Neurol2013; 2013: 159850–159850.
202.
LipGYLarocheCBorianiGCimagliaPDanGASantiniM, et al.. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace2015; 17: 24–31.
203.
LampertRJoskaTBurgMMBatsfordWPMcPhersonCAJainD. Emotional and physical precipitants of ventricular arrhythmia. Circulation2002; 106: 1800–5.
204.
BurgMMLampertRJoskaTBatsfordWJainD. Psychological traits and emotion-triggering of ICD shock-terminated arrhythmias. Psychosom Med2004; 66: 898–902.
205.
WhangWAlbertCMSearsSFJrLampertRContiJBWangPJ, et al.. Depression as a predictor for appropriate shocks among patients with implantable cardioverter-defibrillators: results from the Triggers of Ventricular Arrhythmias (TOVA) study. J Am Coll Cardiol2005; 45: 1090–5.
206.
EakerEDSullivanLMKelly-HayesMD’AgostinoRBSrBenjaminEJ. Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation2004; 109: 1267–71.
207.
EakerEDSullivanLMKelly-HayesMD’AgostinoRBSrBenjaminEJ. Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: the Framingham Offspring Study. Psychosom Med2005; 67: 692–6.
208.
WhangWDavidsonKWConenDTedrowUBEverettBMAlbertCM. Global psychological distress and risk of atrial fibrillation among women: The Women’s Health Study. J Am Heart Assoc2012; 1: e001107–e001107.
209.
QureshiWTAlirhayimZBlahaMJJuraschekSPKeteyianSJBrawnerCA, et al.. Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the Henry Ford Exercise Testing (FIT) Project. Circulation2015; 131: 1827–34.
210.
DrcaNWolkAJensen-UrstadMLarssonSC. Physical activity is associated with a reduced risk of atrial fibrillation in middle-aged and elderly women. Heart2015; 101: 1627–30.
211.
MozaffarianDFurbergCDPsatyBMSiscovickD. Physical activity and incidence of atrial fibrillation in older adults: the Cardiovascular Health Study. Circulation2008; 118: 800–7.
212.
GrimsmoJGrundvoldIMaehlumSArnesenH. High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors-a 28-30 years follow-up study. EurJ Cardiovasc Prev Rehabil2010; 17: 100–5.
213.
MyrstadMNystadWGraff-IversenSThelleDSStigumHAarønæsM, et al.. Effect of years of endurance exercise on risk of atrial fibrillation and atrial flutter. Am J Cardiol2014; 114: 1229–33.
214.
LeeDCPateRRLavieCJSuiXChurchTSBlairSN. Leisure-time running reduces all-cause and cardiovascular mortality risk. J Am Coll Cardiol2014; 64: 472–81.
215.
ThelleDSSelmerRGjesdalKSakshaugSJugessurAGraff-IversenS, et al.. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. Heart2013; 99: 1755–60.
216.
AizerAGazianoJMCookNRMansonJEBuringJEAlbertCM. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol2009; 103: 1572–7.
217.
AndradeJKhairyPDobrevDNattelS. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res2014; 114: 1453–68.
218.
CoumelP. Paroxysmal atrial fibrillation: a disorder of autonomic tone?EurHeart J1994; 15(Suppl A): 9–16.
219.
D’AscenziFCameliMPadelettiMLisiMZacàVNataliB, et al.. Characterization of right atrial function and dimension in top-level athletes: a speckle tracking study. Int J Cardiovasc Imaging2013; 29: 87–94.
220.
D’AndreaARieglerLCocchiaRScarafileRSalernoGGravinoR, et al.. Left atrial volume index in highly trained athletes. Am Heart J2010; 159: 1155–61.
221.
BruggerNKrauseRCarlenFRimensbergerCHilleRSteckH, et al.. Effect of lifetime endurance training on left atrial mechanical function and on the risk of atrial fibrillation. Int J Cardiol2014; 170: 419–25.
222.
BenitoBGay-JordiGSerrano-MollarAGuaschEShiYTardifJC, et al.. Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation2011; 123: 13–22.
223.
LindsayMMDunnFG. Biochemical evidence of myocardial fibrosis in veteran endurance athletes. Br J Sports Med2007; 41: 447–52.
224.
De VosCBNieuwlaatRCrijnsHJCammAJLeHeuzeyJYKirchhofCJ, et al.. Autonomic trigger patterns and antiarrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J2008; 29: 632–9.
225.
O’KeefeJHSchnohrPLavieCJ. The dose of running that best confers longevity. Heart2013; 99: 588–90.
226.
SchnohrPMarottJLLangePJensenGB. Longevity in male and female joggers: the Copenhagen City Heart Study. Am J Epidemiol2013; 177: 683–9.
227.
OfmanPKhawajaORahilly-TierneyCRPeraltaAHoffmeisterPReynoldsMR, et al.. Regular physical activity and risk of atrial fibrillation: a systematic review and meta-analysis. CircArrhythm Electrophysiol2013; 6: 252–6.
228.
KwokCSAndersonSGMyintPKMamasMALokeYK. Physical activity and incidence of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol2014; 177: 467–76.
229.
MontLElosuaRBrugadaJ. Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter. Europace2009; 11: 11–7.
230.
CalvoNRamosPMontserratSGuaschEColl-VinentBDomenechM, et al.. Emerging risk factors and the dose-response relationship between physical activity and lone atrial fibrillation: a prospective case-control study. Europace2016; 18: 57–63.
231.
DrcaNWolkAJensen-UrstadMLarssonSC. Atrial fibrillation is associated with different levels of physical activity levels at different ages in men. Heart2014; 100: 1037–42.
232.
AbdullaJNielsenJR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. Europace2009; 11: 1156–9.
233.
EdelmannFGelbrichGDüngenHDFröhlingSWachterRStahrenbergR, et al.. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. JAm Coll Cardiol2011; 58: 1780–91.
234.
AlingsMSmitMDMoesMLCrijnsHJTijssenJGBrugemannJ, et al.. Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: Background, aims and design of the RACE 3 study. Neth Heart J2013; 21: 354–63.
235.
DarbarDHerronKJBallewJDJahangirAGershPGShenWK, et al.. Familial AF is a genetically heterogeneous disorder. J Am Coll Cardiol2003; 41: 2185–92.
236.
FoxCSPariseHD’AgostinoRBSrLloyd-JonesDMVasanRSWangTJ, et al.. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA2004; 291: 2851–5.
237.
ArnarDOThorvaldssonSManolioTAThorgeirssonGKristjanssonKHakonarsonH, et al.. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J2006; 27: 708–12.
238.
GundlundAChristiansenMNHansenMLOlesenJBZahirDKøberL, et al.. Familial clustering and subsequent incidence of atrial fibrillation among first-degree relatives in Denmark. Europace2016; 18: 658–64.
239.
ZöllerBOhlssonHSundquistJSundquistK. High familial risk of atrial fibrillation/atrial flutter in multiplex families: a nationwide family study in Sweden. J Am Heart Assoc2012; 2: e003384–e003384.
240.
LubitzSAYinXFontesJDMagnaniJWRienstraMPaiM, et al.. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA2010; 304: 2263–9.
241.
OyenNRantheMFCarstensenLBoydHAOlesenMSOlesenSP, et al.. Familial aggregation of lone atrial fibrillation in young persons. J Am Coll Cardiol2012; 60: 917–21.
242.
BrugadaRTappscotTCzernuszewiczGZMarianAJIglesiasAMontL, et al.. Identification of a genetic locus for familial atrial fibrillation. New Engl J Med1997; 336: 905–11.
243.
TuckerNPEllinorPT. Emerging directions in genetics of atrial fibrillation. CircRes2014; 114: 1462–82.
244.
SinnerMFTuckerNRLunettaKLOzakiKSmithJGTrompetS, et al.. Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. Circulation2014; 130: 1225–35.
245.
SmithJGAlmgrenPEngstromGHedbladBPlatonovPGNewton-ChehC, et al.. Genetic polymorphisms for estimating risk of atrial fibrillation: a literature-based meta-analysis. J Intern Med2012; 272: 573–82.
246.
MohantySSantangeliPBaiRDi BiaseLMohantyPPumpA, et al.. Variant rs2200733 on chromosome 4q25 confers increased risk of atrial fibrillation: evidence from a meta-analysis. J Cardiovasc Electrophysiol2013; 24: 155–61.
247.
KirchhofPBreithardtGAliotEAl KhatibSApostolakisSAuricchioA, et al.. Personalized management of atrial fibrillation: proceedings from the fourth atrial fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace2013; 15: 1540–56.
248.
FabritzLGuaschEAntoniadesCBardinetIBenningerGBettsTR, et al.. Expert consensus document: defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol2016; 13: 230–7.
249.
SelmerCOlesenJBHansenMLLindhardsenJSchjerning OlsenAMClausagerJ, et al.. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ2012; 345: e7895–e7895.
250.
FrostLVestergaardPMosekildeL. Hyperthyroidism and risk of atrial fibrillation or flutter. a population-based study. Arch Intern Med2004; 164: 1675–8.
251.
CappolaARFriedLPArnoldAMDaneseMDKullerLHBurkeJL, et al.. Thyroid status, cardiovascular risk and mortality in older adults. JAMA2006; 295: 1033–41.
252.
KimEJLyassAWangNMassaroJMFoxCSBenjaminEJ, et al.. Relation of hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). Am Heart J2014; 167: 123–6.
253.
AuerJScheibnerPMischeTLangstegerWEberOEberB. Subclinical hypothyroidism as a risk factor for atrial fibrillation. Am Heart J2001; 142: 838–42.
254.
GammageMDParleJVHolderRLRobertsLMHobbsFDRWilsonS, et al.. Association between free thyroxine concentration and atrial fibrillation. Arch Intern Med2007; 167: 928–34.
255.
SawinCTGellerAWolfPABelanderAJBakerEBacharachP, et al.. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med1994; 331: 1249–52.
256.
ColletTHGusseklooJBauerDCden ElzenWPJWendyPJCappolaAR, et al.. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med2012; 172: 799–809.
257.
HeeringaJHoogendoornEHvan der DeureWMHofmanAPeetersRPHopWCJ, et al.. High-normal thyroid function and risk of atrial fibrillation. Arch Intern Med2008; 168: 2219–24.
258.
ChakerLHeeringaJDehghanAMediciMVisserWEBaumgartnerC, et al.. Normal thyroid function and the risk of atrial fibrillation: the Rotterdam Study. J Clin Endocrinol Metab2015; 100: 3718–24.
259.
Von OlshausenKBischoffSKahalyGMohr-KahalySErbelRBeyerJ, et al.. Cardiac arrhythmias and heart rate in hyperthyroidism. Am J Cardiol1989; 63: 930–3.
260.
NakazawaHKSakuraiKHamadaNMomotaniNItoK. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med1982; 72: 903–6.
261.
SiuCWJimMHZhangXChanYHPongVKwokJ, et al.. Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced versus non-hyperthyroidism-induced persistent atrial fibrillation. Am J Cardiol2009; 103: 540–3.
262.
MachinoTTadaHSekiguchiYYamasakiHKurokiKIgarashiM, et al.. Prevalence and influence of hyperthyroidism on the long-term outcome of catheter ablation for drug-refractory atrial fibrillation. CircJ2012; 76: 2546–51.
263.
WongcharoenWLinYJChangSLLoLWHuYFChungFP, et al.. History of hyperthyroidism and long-term outcome of catheter ablation of drug-refractory atrial fibrillation. Heart Rhythm2015; 12: 1956–62.
264.
ChanPHHaiJYeungCYLipGYLamKSTseHF, et al.. Benefit of anticoagulation therapy in hyperthyroidism-related atrial fibrillation. Clin Cardiol2015; 38: 476–82.
265.
FribergLRosenqvistMLipGYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J2012; 33: 1500–10.
266.
BruereHFauchierLBernard BrunetAPierreBSimeonEBabutyD, et al.. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation. Am J Med2015; 128: 30–7.
267.
HaissaguerreMJaisPShahDCTakahashiAHociniMQuiniouG, et al.. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med1998; 339: 659–66.
268.
VoigtNDobrevD. Cellular and molecular correlates of ectopic activity in patients with atrial fibrillation. Europace2012; 14(Suppl 5): v97–v105.
269.
KirchhofPLipGYVan GelderICBaxJHylekEKaabS, et al.. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace2012; 14: 8–27.
270.
De JongAMMaassAHOberdorf-MaassSUVan VeldhuisenDJVan GilstWHVan GelderIC. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc Res2011; 89: 754–65.
271.
SchottenUVerheuleSKirchhofPGoetteA. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev2011; 91: 265–325.
272.
VenteclefNGuglielmiVBalseEGaboritBCotillardAAtassiF, et al.. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipofibrokines. Eur Heart J2015; 36: 795–805.
273.
CosioFGAliotEBottoGLHeidbuchelHGellerCJKirchhofP, et al.. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace2008; 10: 21–7.
274.
NattelSGuaschESavelievaI. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J2014; 35: 1448–56.
275.
WellensHJDurrerD. Wolff-Parkinson-White syndrome and atrial fibrillation. Relation between refractory period of accessory pathway and ventricular rate during atrial fibrillation. Am J Cardiol1974; 34: 777–83.
276.
CampbellRWSmithRAGallagherJJPritchettELWallaceAG. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol1977; 40: 514–22.
277.
HamerMEWilkinsonWEClairWKPageRLMcCarthyEAPritchettEL. Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. JAm Coll Cardiol1995; 25: 984–8.
278.
OzcanCStromJBNewellJBMansourMCRuskinJN. Incidence and predictors of atrial fibrillation and its impact on long-term survival in patients with supraventricular arrhythmias. Europace2014; 16: 1508–14.
279.
WaldoAL. Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin?Cardiovasc Res2002; 54: 217–29.
280.
LinCHChangSLHuangHKLoLWLinYJChiangCH, et al.. Novel electrophysiological characteristics of atrioventricular nodal continuous conduction curves in atrioventricular nodal re-entrant tachycardia with concomitant cavotricuspid isthmus-dependent atrial flutter. Europace2015; pii: euv345–euv345.
281.
ChenYJChenSATaiCTWenZCFengANDingYA, et al.. Role of atrial electrophysiology and autonomic nervous system in patients with supraventricular tachycardia and paroxysmal atrial fibrillation. JAm Coll Cardiol1998; 32: 732–8.
282.
SticherlingCOralHHorrocksJChoughSPBakerRLKimMH, et al.. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation2000; 102: 2503–8.
283.
CrijnsHJGMLieKI. Hemodynamic deterioration after treatment with adenosine. Br Heart J1995; 73: 103–103.
284.
NabarARodriguezLMTimmermansCVan den DoolASmeetsJLRMWellensHJJ. Observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation. Circulation1999; 99: 1441–5.
285.
PentingaMLMeederJGCrijnsHJGMDe MuinckEDWiesfeldACPLieKI. Late onset atrioventricular nodal tachycardia. Int J Cardiol1993; 38: 293–8.
286.
WellensHJ. When to perform catheter ablation in asymptomatic patients with a Wolff-Parkinson-White electrocardiogram. Circulation2005; 112: 2201–16.
HaissaguerreMFischerBLabbeTLemetayerPMontserratPd’IvernoisC, et al.. Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways. Am J Cardiol1992; 69: 493–7.
289.
PapponeCSantinelliV. Catheter ablation should be performed in asymptomatic patients with Wolff-Parkinson-White syndrome. Circulation2005; 112: 2207–16.
290.
McKeownPPGuttermanD. Executive summary: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest2005; 128: 1S–5S.
291.
ShariffNZelenkofskeSEidSWeissMJMohammedMQ. Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery. BMC Cardiovasc Disord2010; 8: 10–7.
292.
ShantsilaEWatsonTLipGY. Atrial fibrillation post-cardiac surgery: changing perspectives. Curr Med Res Opin2006; 22: 1437–41.
293.
Sanchez-QuiñonesJMarínFRoldánVLipGY. The impact of statin use on atrial fibrillation. QJM2008; 101: 845–61.
294.
NairSG. Atrial fibrillation after cardiac surgery. Ann Card Anaesth2010; 13: 196–205.
295.
CrystalEConnollySJSleikKGingerTJYusufS. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation2002; 106: 75–80.
296.
JidéusLBlomströmPNilssonLStridsbergMHansellPBlomström-LundqvistC. Tachyarrhythmias and triggering factors for atrial fibrillation after coronary artery bypass operations. Ann Thorac Surg2000; 69: 1064–9.
297.
ArsenaultKAYusufAMCrystalEHealeyJSMorilloCANairGM, et al.. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev2013; 1: CD003611–CD003611.
298.
BagshawSMGalbraithPDMitchellLBSauveRExnerDVGhaliWA. Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg2006; 82: 1927–37.
299.
PattiGChelloMCanduraDPasceriVD’AmbrosioACovinoE, et al.. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation2006; 114: 1455–61.
Orenes-PiñeroEMontoro-GarcíaSBanerjeeAValdésMLipGYHMarínF. Pre and post-operative treatments for prevention of atrial fibrillation after cardiac surgery. Mini Rev Med Chem2012; 12: 1419–31.
302.
HoKMTanJA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation2009; 119: 1853–66.
303.
SavelievaIKakourosNKourliourosACammJA. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace2011; 13: 308–28.
304.
SavelievaIKakourosNKourliourosACammJA. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace2011; 13: 610–25.
305.
MadridAHBuenoMGRebolloJMMarinIPeñaGBernalE, et al.. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation2002; 106: 331–6.
306.
SwedbergKZannadFMcMurrayJJKrumHvan VeldhuisenDJShiH, et al.. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. JAm Coll Cardiol2012; 59: 1598–603.
307.
LiuTKorantzopoulosPShaoQZhangZLetsasKPLiG. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. Europace2016; 18: 672–8.
308.
LipGYHLLaneD. Stroke prevention in atrial fibrillation. A systematic review. JAMA2015; 313: 1950–62.
309.
PistersRLaneDAMarinFCammAJLipGY. Stroke and thromboembolism in atrial fibrillation. CircJ2012; 76: 2289–304.
310.
LipGYHLNieuwlaatRPistersRLaneDACrijnsHJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest2010; 137: 263–72.
311.
LambertsMNielsenOWLipGYRuwaldMHChristiansenCBKristensenSL, et al.. Cardiovascular risk in patients with sleep apnoea with or without continuous positive airway pressure therapy: follow-up of 4.5 million Danish adults. J Intern Med2014; 276: 659–66.
312.
FribergLBensonLLipGY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J2015; 36: 297–306.
313.
AgarwalMApostolakisSLaneDALipGY. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther2014; 36: 1135–44.
314.
LipGYHLFrisonLGrindM. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J2007; 28: 752–9.
315.
OvervadTFRasmussenLHSkjothFOvervadKAlbertsenIELaneDA, et al.. Alcohol intake and prognosis of atrial fibrillation. Heart (Br Card Soc)2013; 99: 1093–9.
316.
AlbertsenIERasmussenLHLaneDAOvervadTFSkjothFOvervadK, et al.. The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. Chest2014; 145: 559–66.
317.
CalkinsHKuckKHCappatoRBrugadaJCammAJChenSA, et al.. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace2012; 14: 528–606.
318.
BunchTJMayHTBairTLWeissJPCrandallBGOsbornJS, et al.. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm2013; 10: 1272–7.
319.
De CaterinaRHustedSWallentinLAndreottiFArnesenHBachmannF, et al.. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost2013; 110: 1087–107.
320.
GallegoPRoldanVMarinFRomeraMValdesMVicenteV, et al.. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost2013; 110: 1189–98.
321.
AzoulayLDell’AnielloSSimonTARenouxCSuissaS. Initiation ofwarfarin in patients with atrial fibrillation: early effects on ischaemic strokes. EurHeartJ2014; 35: 1881–7.
322.
ApostolakisSSullivanRMOlshanskyBLipGY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest2013; 144: 1555–63.
323.
ProiettiMLipGY. Simple decision making between a vitamin K Antagonist and Non-Vitamin K Antagonist Oral Anticoagulant (NOACs): using the SAMe-TT2R2 Score. Eur Heart J Cardiovasc Pharmacother2015; 1: 150–2.
324.
DogliottiAGiuglianoRP. A novel approach indirectly comparing benefit-risk balance across anti-thrombotic therapies in patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother2015; 1: 15–28.
325.
LipGYHaguenoerKSaint-EtienneCFauchierL. Relationship of the SAME-TT2R2score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation. Chest2014; 146: 719–26.
326.
LaneDAAguinagaLBlomström-LundqvistCBorianiGDanGAHillsMT, et al.. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacicon Cardfacay Electrofisiologia (SOLEACE). Europace2015; 17: 1747–69.
